https://keshavmed.com/news/dr-reddys-presses-pause-on-generic-semaglutide-supply-after-flagging-api-issue-zh-tw/ 2026-07-11T06:34:20+00:00 https://keshavmed.com/news/phase-iii-data-support-single-tablet-hiv-1-therapy-for-older-adults-with-resistant-infection-inside-precision-medicine-ms/ 2026-07-11T06:34:20+00:00 https://keshavmed.com/news/dr-reddys-presses-pause-on-generic-semaglutide-supply-after-flagging-api-issue-de/ 2026-07-11T06:34:19+00:00 https://keshavmed.com/news/dr-reddys-presses-pause-on-generic-semaglutide-supply-after-flagging-api-issue-ja/ 2026-07-11T06:34:19+00:00 https://keshavmed.com/news/dr-reddys-presses-pause-on-generic-semaglutide-supply-after-flagging-api-issue-pt/ 2026-07-11T06:34:19+00:00 https://keshavmed.com/news/dr-reddys-presses-pause-on-generic-semaglutide-supply-after-flagging-api-issue-es/ 2026-07-11T06:34:19+00:00 https://keshavmed.com/news/dr-reddys-presses-pause-on-generic-semaglutide-supply-after-flagging-api-issue-ar/ 2026-07-11T06:34:19+00:00 https://keshavmed.com/news/dr-reddys-presses-pause-on-generic-semaglutide-supply-after-flagging-api-issue-ru/ 2026-07-11T06:34:19+00:00 https://keshavmed.com/news/dr-reddys-presses-pause-on-generic-semaglutide-supply-after-flagging-api-issue-id/ 2026-07-11T06:34:19+00:00 https://keshavmed.com/news/dr-reddys-presses-pause-on-generic-semaglutide-supply-after-flagging-api-issue-th/ 2026-07-11T06:34:19+00:00 https://keshavmed.com/news/dr-reddys-presses-pause-on-generic-semaglutide-supply-after-flagging-api-issue-vi/ 2026-07-11T06:34:19+00:00 https://keshavmed.com/news/dr-reddys-presses-pause-on-generic-semaglutide-supply-after-flagging-api-issue-ms/ 2026-07-11T06:34:19+00:00 https://keshavmed.com/news/sunitinib-malate-capsule-northstar-rxllc/ 2026-07-11T06:34:19+00:00 https://keshavmed.com/news/sunitinib-malate-capsule-northstar-rxllc-zh-tw/ 2026-07-11T06:34:19+00:00 https://keshavmed.com/news/sunitinib-malate-capsule-northstar-rxllc-fr/ 2026-07-11T06:34:19+00:00 https://keshavmed.com/news/sunitinib-malate-capsule-northstar-rxllc-de/ 2026-07-11T06:34:19+00:00 https://keshavmed.com/news/dr-reddys-presses-pause-on-generic-semaglutide-supply-after-flagging-api-issue-fr/ 2026-07-11T06:34:19+00:00 https://keshavmed.com/news/sunitinib-malate-capsule-northstar-rxllc-es/ 2026-07-11T06:34:18+00:00 https://keshavmed.com/news/sunitinib-malate-capsule-northstar-rxllc-ar/ 2026-07-11T06:34:18+00:00 https://keshavmed.com/news/sunitinib-malate-capsule-northstar-rxllc-ru/ 2026-07-11T06:34:18+00:00 https://keshavmed.com/news/sunitinib-malate-capsule-northstar-rxllc-ja/ 2026-07-11T06:34:18+00:00 https://keshavmed.com/news/sunitinib-malate-capsule-northstar-rxllc-pt/ 2026-07-11T06:34:18+00:00 https://keshavmed.com/news/sunitinib-malate-capsule-northstar-rxllc-id/ 2026-07-11T06:34:17+00:00 https://keshavmed.com/news/sunitinib-malate-capsule-northstar-rxllc-th/ 2026-07-11T06:34:17+00:00 https://keshavmed.com/news/sunitinib-malate-capsule-northstar-rxllc-vi/ 2026-07-11T06:34:17+00:00 https://keshavmed.com/news/%e4%b8%89%e6%9c%9f%e4%b8%b4%e5%ba%8a%e8%af%95%e9%aa%8c%e7%bb%93%e6%9e%9c%e5%8f%91%e5%b8%83%ef%bc%81%e6%9d%8e%e5%bb%ba%e5%8b%87-%e9%82%b1%e5%bd%95%e8%b4%b5%e5%9b%a2%e9%98%9fsttt%e5%8f%91%e6%96%87-2-ru/ 2026-07-11T06:34:16+00:00 https://keshavmed.com/news/%e4%b8%89%e6%9c%9f%e4%b8%b4%e5%ba%8a%e8%af%95%e9%aa%8c%e7%bb%93%e6%9e%9c%e5%8f%91%e5%b8%83%ef%bc%81%e6%9d%8e%e5%bb%ba%e5%8b%87-%e9%82%b1%e5%bd%95%e8%b4%b5%e5%9b%a2%e9%98%9fsttt%e5%8f%91%e6%96%87-2-id/ 2026-07-11T06:34:16+00:00 https://keshavmed.com/news/%e4%b8%89%e6%9c%9f%e4%b8%b4%e5%ba%8a%e8%af%95%e9%aa%8c%e7%bb%93%e6%9e%9c%e5%8f%91%e5%b8%83%ef%bc%81%e6%9d%8e%e5%bb%ba%e5%8b%87-%e9%82%b1%e5%bd%95%e8%b4%b5%e5%9b%a2%e9%98%9fsttt%e5%8f%91%e6%96%87-2-th/ 2026-07-11T06:34:16+00:00 https://keshavmed.com/news/sunitinib-malate-capsule-northstar-rxllc-ms/ 2026-07-11T06:34:16+00:00 https://keshavmed.com/news/%e4%b8%89%e6%9c%9f%e4%b8%b4%e5%ba%8a%e8%af%95%e9%aa%8c%e7%bb%93%e6%9e%9c%e5%8f%91%e5%b8%83%ef%bc%81%e6%9d%8e%e5%bb%ba%e5%8b%87-%e9%82%b1%e5%bd%95%e8%b4%b5%e5%9b%a2%e9%98%9fsttt%e5%8f%91%e6%96%87-2/ 2026-07-11T06:34:16+00:00 https://keshavmed.com/news/%e4%b8%89%e6%9c%9f%e4%b8%b4%e5%ba%8a%e8%af%95%e9%aa%8c%e7%bb%93%e6%9e%9c%e5%8f%91%e5%b8%83%ef%bc%81%e6%9d%8e%e5%bb%ba%e5%8b%87-%e9%82%b1%e5%bd%95%e8%b4%b5%e5%9b%a2%e9%98%9fsttt%e5%8f%91%e6%96%87-2-zh/ 2026-07-11T06:34:16+00:00 https://keshavmed.com/news/%e4%b8%89%e6%9c%9f%e4%b8%b4%e5%ba%8a%e8%af%95%e9%aa%8c%e7%bb%93%e6%9e%9c%e5%8f%91%e5%b8%83%ef%bc%81%e6%9d%8e%e5%bb%ba%e5%8b%87-%e9%82%b1%e5%bd%95%e8%b4%b5%e5%9b%a2%e9%98%9fsttt%e5%8f%91%e6%96%87-2-en/ 2026-07-11T06:34:16+00:00 https://keshavmed.com/news/%e4%b8%89%e6%9c%9f%e4%b8%b4%e5%ba%8a%e8%af%95%e9%aa%8c%e7%bb%93%e6%9e%9c%e5%8f%91%e5%b8%83%ef%bc%81%e6%9d%8e%e5%bb%ba%e5%8b%87-%e9%82%b1%e5%bd%95%e8%b4%b5%e5%9b%a2%e9%98%9fsttt%e5%8f%91%e6%96%87-2-fr/ 2026-07-11T06:34:16+00:00 https://keshavmed.com/news/%e4%b8%89%e6%9c%9f%e4%b8%b4%e5%ba%8a%e8%af%95%e9%aa%8c%e7%bb%93%e6%9e%9c%e5%8f%91%e5%b8%83%ef%bc%81%e6%9d%8e%e5%bb%ba%e5%8b%87-%e9%82%b1%e5%bd%95%e8%b4%b5%e5%9b%a2%e9%98%9fsttt%e5%8f%91%e6%96%87-2-de/ 2026-07-11T06:34:16+00:00 https://keshavmed.com/news/%e4%b8%89%e6%9c%9f%e4%b8%b4%e5%ba%8a%e8%af%95%e9%aa%8c%e7%bb%93%e6%9e%9c%e5%8f%91%e5%b8%83%ef%bc%81%e6%9d%8e%e5%bb%ba%e5%8b%87-%e9%82%b1%e5%bd%95%e8%b4%b5%e5%9b%a2%e9%98%9fsttt%e5%8f%91%e6%96%87-2-ja/ 2026-07-11T06:34:16+00:00 https://keshavmed.com/news/%e4%b8%89%e6%9c%9f%e4%b8%b4%e5%ba%8a%e8%af%95%e9%aa%8c%e7%bb%93%e6%9e%9c%e5%8f%91%e5%b8%83%ef%bc%81%e6%9d%8e%e5%bb%ba%e5%8b%87-%e9%82%b1%e5%bd%95%e8%b4%b5%e5%9b%a2%e9%98%9fsttt%e5%8f%91%e6%96%87-2-pt/ 2026-07-11T06:34:16+00:00 https://keshavmed.com/news/%e4%b8%89%e6%9c%9f%e4%b8%b4%e5%ba%8a%e8%af%95%e9%aa%8c%e7%bb%93%e6%9e%9c%e5%8f%91%e5%b8%83%ef%bc%81%e6%9d%8e%e5%bb%ba%e5%8b%87-%e9%82%b1%e5%bd%95%e8%b4%b5%e5%9b%a2%e9%98%9fsttt%e5%8f%91%e6%96%87-2-es/ 2026-07-11T06:34:16+00:00 https://keshavmed.com/news/%e4%b8%89%e6%9c%9f%e4%b8%b4%e5%ba%8a%e8%af%95%e9%aa%8c%e7%bb%93%e6%9e%9c%e5%8f%91%e5%b8%83%ef%bc%81%e6%9d%8e%e5%bb%ba%e5%8b%87-%e9%82%b1%e5%bd%95%e8%b4%b5%e5%9b%a2%e9%98%9fsttt%e5%8f%91%e6%96%87-2-ar/ 2026-07-11T06:34:16+00:00 https://keshavmed.com/news/katelyn-daniels%d6%89-final-results-of-venetoclax-combination-therapy-in-relapsed-or-refractory-aml-oncodaily-vi/ 2026-07-11T06:34:15+00:00 https://keshavmed.com/news/katelyn-daniels%d6%89-final-results-of-venetoclax-combination-therapy-in-relapsed-or-refractory-aml-oncodaily-ms/ 2026-07-11T06:34:15+00:00 https://keshavmed.com/news/osimertinib-after-chemoradiotherapy-shows-manageable-safety-in-nsclc-targeted-oncology/ 2026-07-11T06:34:15+00:00 https://keshavmed.com/news/%e4%b8%89%e6%9c%9f%e4%b8%b4%e5%ba%8a%e8%af%95%e9%aa%8c%e7%bb%93%e6%9e%9c%e5%8f%91%e5%b8%83%ef%bc%81%e6%9d%8e%e5%bb%ba%e5%8b%87-%e9%82%b1%e5%bd%95%e8%b4%b5%e5%9b%a2%e9%98%9fsttt%e5%8f%91%e6%96%87-2-vi/ 2026-07-11T06:34:15+00:00 https://keshavmed.com/news/osimertinib-after-chemoradiotherapy-shows-manageable-safety-in-nsclc-targeted-oncology-zh-tw/ 2026-07-11T06:34:15+00:00 https://keshavmed.com/news/%e4%b8%89%e6%9c%9f%e4%b8%b4%e5%ba%8a%e8%af%95%e9%aa%8c%e7%bb%93%e6%9e%9c%e5%8f%91%e5%b8%83%ef%bc%81%e6%9d%8e%e5%bb%ba%e5%8b%87-%e9%82%b1%e5%bd%95%e8%b4%b5%e5%9b%a2%e9%98%9fsttt%e5%8f%91%e6%96%87-2-ms/ 2026-07-11T06:34:15+00:00 https://keshavmed.com/news/osimertinib-after-chemoradiotherapy-shows-manageable-safety-in-nsclc-targeted-oncology-fr/ 2026-07-11T06:34:15+00:00 https://keshavmed.com/news/katelyn-daniels%d6%89-final-results-of-venetoclax-combination-therapy-in-relapsed-or-refractory-aml-oncodaily/ 2026-07-11T06:34:15+00:00 https://keshavmed.com/news/osimertinib-after-chemoradiotherapy-shows-manageable-safety-in-nsclc-targeted-oncology-de/ 2026-07-11T06:34:15+00:00 https://keshavmed.com/news/katelyn-daniels%d6%89-final-results-of-venetoclax-combination-therapy-in-relapsed-or-refractory-aml-oncodaily-zh-tw/ 2026-07-11T06:34:15+00:00 https://keshavmed.com/news/osimertinib-after-chemoradiotherapy-shows-manageable-safety-in-nsclc-targeted-oncology-ja/ 2026-07-11T06:34:15+00:00 https://keshavmed.com/news/katelyn-daniels%d6%89-final-results-of-venetoclax-combination-therapy-in-relapsed-or-refractory-aml-oncodaily-fr/ 2026-07-11T06:34:15+00:00 https://keshavmed.com/news/osimertinib-after-chemoradiotherapy-shows-manageable-safety-in-nsclc-targeted-oncology-pt/ 2026-07-11T06:34:15+00:00 https://keshavmed.com/news/katelyn-daniels%d6%89-final-results-of-venetoclax-combination-therapy-in-relapsed-or-refractory-aml-oncodaily-de/ 2026-07-11T06:34:15+00:00 https://keshavmed.com/news/katelyn-daniels%d6%89-final-results-of-venetoclax-combination-therapy-in-relapsed-or-refractory-aml-oncodaily-ja/ 2026-07-11T06:34:15+00:00 https://keshavmed.com/news/katelyn-daniels%d6%89-final-results-of-venetoclax-combination-therapy-in-relapsed-or-refractory-aml-oncodaily-pt/ 2026-07-11T06:34:15+00:00 https://keshavmed.com/news/katelyn-daniels%d6%89-final-results-of-venetoclax-combination-therapy-in-relapsed-or-refractory-aml-oncodaily-es/ 2026-07-11T06:34:15+00:00 https://keshavmed.com/news/katelyn-daniels%d6%89-final-results-of-venetoclax-combination-therapy-in-relapsed-or-refractory-aml-oncodaily-ar/ 2026-07-11T06:34:15+00:00 https://keshavmed.com/news/katelyn-daniels%d6%89-final-results-of-venetoclax-combination-therapy-in-relapsed-or-refractory-aml-oncodaily-ru/ 2026-07-11T06:34:15+00:00 https://keshavmed.com/news/katelyn-daniels%d6%89-final-results-of-venetoclax-combination-therapy-in-relapsed-or-refractory-aml-oncodaily-id/ 2026-07-11T06:34:15+00:00 https://keshavmed.com/news/katelyn-daniels%d6%89-final-results-of-venetoclax-combination-therapy-in-relapsed-or-refractory-aml-oncodaily-th/ 2026-07-11T06:34:15+00:00 https://keshavmed.com/news/%e6%96%b0%e5%9e%8brason-%e6%8a%91%e5%88%b6%e5%89%82zoldonrasib%e4%b8%8edaraxonrasib%e5%8f%af%e5%85%8b%e6%9c%8d%e5%ae%9e%e4%bd%93%e7%98%a4%e5%af%b9%e4%bc%a0%e7%bb%9f-kras-%e6%8a%91%e5%88%b6%e5%89%82-zh/ 2026-07-11T06:34:14+00:00 https://keshavmed.com/news/%e6%96%b0%e5%9e%8brason-%e6%8a%91%e5%88%b6%e5%89%82zoldonrasib%e4%b8%8edaraxonrasib%e5%8f%af%e5%85%8b%e6%9c%8d%e5%ae%9e%e4%bd%93%e7%98%a4%e5%af%b9%e4%bc%a0%e7%bb%9f-kras-%e6%8a%91%e5%88%b6%e5%89%82-en/ 2026-07-11T06:34:14+00:00 https://keshavmed.com/news/%e6%96%b0%e5%9e%8brason-%e6%8a%91%e5%88%b6%e5%89%82zoldonrasib%e4%b8%8edaraxonrasib%e5%8f%af%e5%85%8b%e6%9c%8d%e5%ae%9e%e4%bd%93%e7%98%a4%e5%af%b9%e4%bc%a0%e7%bb%9f-kras-%e6%8a%91%e5%88%b6%e5%89%82-fr/ 2026-07-11T06:34:14+00:00 https://keshavmed.com/news/%e6%96%b0%e5%9e%8brason-%e6%8a%91%e5%88%b6%e5%89%82zoldonrasib%e4%b8%8edaraxonrasib%e5%8f%af%e5%85%8b%e6%9c%8d%e5%ae%9e%e4%bd%93%e7%98%a4%e5%af%b9%e4%bc%a0%e7%bb%9f-kras-%e6%8a%91%e5%88%b6%e5%89%82-de/ 2026-07-11T06:34:14+00:00 https://keshavmed.com/news/%e6%96%b0%e5%9e%8brason-%e6%8a%91%e5%88%b6%e5%89%82zoldonrasib%e4%b8%8edaraxonrasib%e5%8f%af%e5%85%8b%e6%9c%8d%e5%ae%9e%e4%bd%93%e7%98%a4%e5%af%b9%e4%bc%a0%e7%bb%9f-kras-%e6%8a%91%e5%88%b6%e5%89%82-ja/ 2026-07-11T06:34:14+00:00 https://keshavmed.com/news/%e6%96%b0%e5%9e%8brason-%e6%8a%91%e5%88%b6%e5%89%82zoldonrasib%e4%b8%8edaraxonrasib%e5%8f%af%e5%85%8b%e6%9c%8d%e5%ae%9e%e4%bd%93%e7%98%a4%e5%af%b9%e4%bc%a0%e7%bb%9f-kras-%e6%8a%91%e5%88%b6%e5%89%82-pt/ 2026-07-11T06:34:14+00:00 https://keshavmed.com/news/%e6%96%b0%e5%9e%8brason-%e6%8a%91%e5%88%b6%e5%89%82zoldonrasib%e4%b8%8edaraxonrasib%e5%8f%af%e5%85%8b%e6%9c%8d%e5%ae%9e%e4%bd%93%e7%98%a4%e5%af%b9%e4%bc%a0%e7%bb%9f-kras-%e6%8a%91%e5%88%b6%e5%89%82-es/ 2026-07-11T06:34:14+00:00 https://keshavmed.com/news/%e6%96%b0%e5%9e%8brason-%e6%8a%91%e5%88%b6%e5%89%82zoldonrasib%e4%b8%8edaraxonrasib%e5%8f%af%e5%85%8b%e6%9c%8d%e5%ae%9e%e4%bd%93%e7%98%a4%e5%af%b9%e4%bc%a0%e7%bb%9f-kras-%e6%8a%91%e5%88%b6%e5%89%82-ar/ 2026-07-11T06:34:14+00:00 https://keshavmed.com/news/osimertinib-after-chemoradiotherapy-shows-manageable-safety-in-nsclc-targeted-oncology-es/ 2026-07-11T06:34:14+00:00 https://keshavmed.com/news/%e6%96%b0%e5%9e%8brason-%e6%8a%91%e5%88%b6%e5%89%82zoldonrasib%e4%b8%8edaraxonrasib%e5%8f%af%e5%85%8b%e6%9c%8d%e5%ae%9e%e4%bd%93%e7%98%a4%e5%af%b9%e4%bc%a0%e7%bb%9f-kras-%e6%8a%91%e5%88%b6%e5%89%82-ru/ 2026-07-11T06:34:14+00:00 https://keshavmed.com/news/osimertinib-after-chemoradiotherapy-shows-manageable-safety-in-nsclc-targeted-oncology-ar/ 2026-07-11T06:34:14+00:00 https://keshavmed.com/news/osimertinib-after-chemoradiotherapy-shows-manageable-safety-in-nsclc-targeted-oncology-ru/ 2026-07-11T06:34:14+00:00 https://keshavmed.com/news/osimertinib-after-chemoradiotherapy-shows-manageable-safety-in-nsclc-targeted-oncology-id/ 2026-07-11T06:34:14+00:00 https://keshavmed.com/news/osimertinib-after-chemoradiotherapy-shows-manageable-safety-in-nsclc-targeted-oncology-th/ 2026-07-11T06:34:14+00:00 https://keshavmed.com/news/osimertinib-after-chemoradiotherapy-shows-manageable-safety-in-nsclc-targeted-oncology-vi/ 2026-07-11T06:34:14+00:00 https://keshavmed.com/news/osimertinib-after-chemoradiotherapy-shows-manageable-safety-in-nsclc-targeted-oncology-ms/ 2026-07-11T06:34:14+00:00 https://keshavmed.com/news/%e6%96%b0%e5%9e%8brason-%e6%8a%91%e5%88%b6%e5%89%82zoldonrasib%e4%b8%8edaraxonrasib%e5%8f%af%e5%85%8b%e6%9c%8d%e5%ae%9e%e4%bd%93%e7%98%a4%e5%af%b9%e4%bc%a0%e7%bb%9f-kras-%e6%8a%91%e5%88%b6%e5%89%82/ 2026-07-11T06:34:14+00:00 https://keshavmed.com/news/post-hoc-analysis-of-the-admiral-and-commodore-trials-timing-of-response-with-gilteritinib-monotherapy-in-r-r-flt3m-aml-aml-hub-com-de/ 2026-07-11T06:34:13+00:00 https://keshavmed.com/news/post-hoc-analysis-of-the-admiral-and-commodore-trials-timing-of-response-with-gilteritinib-monotherapy-in-r-r-flt3m-aml-aml-hub-com-ja/ 2026-07-11T06:34:13+00:00 https://keshavmed.com/news/post-hoc-analysis-of-the-admiral-and-commodore-trials-timing-of-response-with-gilteritinib-monotherapy-in-r-r-flt3m-aml-aml-hub-com-pt/ 2026-07-11T06:34:13+00:00 https://keshavmed.com/news/post-hoc-analysis-of-the-admiral-and-commodore-trials-timing-of-response-with-gilteritinib-monotherapy-in-r-r-flt3m-aml-aml-hub-com-es/ 2026-07-11T06:34:13+00:00 https://keshavmed.com/news/post-hoc-analysis-of-the-admiral-and-commodore-trials-timing-of-response-with-gilteritinib-monotherapy-in-r-r-flt3m-aml-aml-hub-com-ar/ 2026-07-11T06:34:13+00:00 https://keshavmed.com/news/post-hoc-analysis-of-the-admiral-and-commodore-trials-timing-of-response-with-gilteritinib-monotherapy-in-r-r-flt3m-aml-aml-hub-com-ru/ 2026-07-11T06:34:13+00:00 https://keshavmed.com/news/post-hoc-analysis-of-the-admiral-and-commodore-trials-timing-of-response-with-gilteritinib-monotherapy-in-r-r-flt3m-aml-aml-hub-com-id/ 2026-07-11T06:34:13+00:00 https://keshavmed.com/news/post-hoc-analysis-of-the-admiral-and-commodore-trials-timing-of-response-with-gilteritinib-monotherapy-in-r-r-flt3m-aml-aml-hub-com-th/ 2026-07-11T06:34:13+00:00 https://keshavmed.com/news/post-hoc-analysis-of-the-admiral-and-commodore-trials-timing-of-response-with-gilteritinib-monotherapy-in-r-r-flt3m-aml-aml-hub-com-vi/ 2026-07-11T06:34:13+00:00 https://keshavmed.com/news/%e6%96%b0%e5%9e%8brason-%e6%8a%91%e5%88%b6%e5%89%82zoldonrasib%e4%b8%8edaraxonrasib%e5%8f%af%e5%85%8b%e6%9c%8d%e5%ae%9e%e4%bd%93%e7%98%a4%e5%af%b9%e4%bc%a0%e7%bb%9f-kras-%e6%8a%91%e5%88%b6%e5%89%82-id/ 2026-07-11T06:34:13+00:00 https://keshavmed.com/news/post-hoc-analysis-of-the-admiral-and-commodore-trials-timing-of-response-with-gilteritinib-monotherapy-in-r-r-flt3m-aml-aml-hub-com-ms/ 2026-07-11T06:34:13+00:00 https://keshavmed.com/news/%e6%96%b0%e5%9e%8brason-%e6%8a%91%e5%88%b6%e5%89%82zoldonrasib%e4%b8%8edaraxonrasib%e5%8f%af%e5%85%8b%e6%9c%8d%e5%ae%9e%e4%bd%93%e7%98%a4%e5%af%b9%e4%bc%a0%e7%bb%9f-kras-%e6%8a%91%e5%88%b6%e5%89%82-th/ 2026-07-11T06:34:13+00:00 https://keshavmed.com/news/post-marketing-pharmacovigilance-study-of-gilteritinib-and-midostaurin-from-the-faers-database-aml-hub-com/ 2026-07-11T06:34:13+00:00 https://keshavmed.com/news/%e6%96%b0%e5%9e%8brason-%e6%8a%91%e5%88%b6%e5%89%82zoldonrasib%e4%b8%8edaraxonrasib%e5%8f%af%e5%85%8b%e6%9c%8d%e5%ae%9e%e4%bd%93%e7%98%a4%e5%af%b9%e4%bc%a0%e7%bb%9f-kras-%e6%8a%91%e5%88%b6%e5%89%82-vi/ 2026-07-11T06:34:13+00:00 https://keshavmed.com/news/%e6%96%b0%e5%9e%8brason-%e6%8a%91%e5%88%b6%e5%89%82zoldonrasib%e4%b8%8edaraxonrasib%e5%8f%af%e5%85%8b%e6%9c%8d%e5%ae%9e%e4%bd%93%e7%98%a4%e5%af%b9%e4%bc%a0%e7%bb%9f-kras-%e6%8a%91%e5%88%b6%e5%89%82-ms/ 2026-07-11T06:34:13+00:00 https://keshavmed.com/news/post-hoc-analysis-of-the-admiral-and-commodore-trials-timing-of-response-with-gilteritinib-monotherapy-in-r-r-flt3m-aml-aml-hub-com/ 2026-07-11T06:34:13+00:00 https://keshavmed.com/news/post-hoc-analysis-of-the-admiral-and-commodore-trials-timing-of-response-with-gilteritinib-monotherapy-in-r-r-flt3m-aml-aml-hub-com-zh-tw/ 2026-07-11T06:34:13+00:00 https://keshavmed.com/news/post-hoc-analysis-of-the-admiral-and-commodore-trials-timing-of-response-with-gilteritinib-monotherapy-in-r-r-flt3m-aml-aml-hub-com-fr/ 2026-07-11T06:34:13+00:00 https://keshavmed.com/news/post-marketing-pharmacovigilance-study-of-gilteritinib-and-midostaurin-from-the-faers-database-aml-hub-com-es/ 2026-07-11T06:34:12+00:00 https://keshavmed.com/news/cholesterol-inhibition-enhances-antitumor-response-of-gilteritinib-in-lung-cancer-cells-nature-id/ 2026-07-11T06:34:12+00:00 https://keshavmed.com/news/post-marketing-pharmacovigilance-study-of-gilteritinib-and-midostaurin-from-the-faers-database-aml-hub-com-ar/ 2026-07-11T06:34:12+00:00 https://keshavmed.com/news/post-marketing-pharmacovigilance-study-of-gilteritinib-and-midostaurin-from-the-faers-database-aml-hub-com-ru/ 2026-07-11T06:34:12+00:00 https://keshavmed.com/news/post-marketing-pharmacovigilance-study-of-gilteritinib-and-midostaurin-from-the-faers-database-aml-hub-com-id/ 2026-07-11T06:34:12+00:00 https://keshavmed.com/news/post-marketing-pharmacovigilance-study-of-gilteritinib-and-midostaurin-from-the-faers-database-aml-hub-com-th/ 2026-07-11T06:34:12+00:00 https://keshavmed.com/news/post-marketing-pharmacovigilance-study-of-gilteritinib-and-midostaurin-from-the-faers-database-aml-hub-com-vi/ 2026-07-11T06:34:12+00:00 https://keshavmed.com/news/post-marketing-pharmacovigilance-study-of-gilteritinib-and-midostaurin-from-the-faers-database-aml-hub-com-ms/ 2026-07-11T06:34:12+00:00 https://keshavmed.com/news/cholesterol-inhibition-enhances-antitumor-response-of-gilteritinib-in-lung-cancer-cells-nature/ 2026-07-11T06:34:12+00:00 https://keshavmed.com/news/cholesterol-inhibition-enhances-antitumor-response-of-gilteritinib-in-lung-cancer-cells-nature-zh-tw/ 2026-07-11T06:34:12+00:00 https://keshavmed.com/news/cholesterol-inhibition-enhances-antitumor-response-of-gilteritinib-in-lung-cancer-cells-nature-fr/ 2026-07-11T06:34:12+00:00 https://keshavmed.com/news/cholesterol-inhibition-enhances-antitumor-response-of-gilteritinib-in-lung-cancer-cells-nature-de/ 2026-07-11T06:34:12+00:00 https://keshavmed.com/news/post-marketing-pharmacovigilance-study-of-gilteritinib-and-midostaurin-from-the-faers-database-aml-hub-com-zh-tw/ 2026-07-11T06:34:12+00:00 https://keshavmed.com/news/cholesterol-inhibition-enhances-antitumor-response-of-gilteritinib-in-lung-cancer-cells-nature-ja/ 2026-07-11T06:34:12+00:00 https://keshavmed.com/news/post-marketing-pharmacovigilance-study-of-gilteritinib-and-midostaurin-from-the-faers-database-aml-hub-com-fr/ 2026-07-11T06:34:12+00:00 https://keshavmed.com/news/cholesterol-inhibition-enhances-antitumor-response-of-gilteritinib-in-lung-cancer-cells-nature-pt/ 2026-07-11T06:34:12+00:00 https://keshavmed.com/news/post-marketing-pharmacovigilance-study-of-gilteritinib-and-midostaurin-from-the-faers-database-aml-hub-com-de/ 2026-07-11T06:34:12+00:00 https://keshavmed.com/news/cholesterol-inhibition-enhances-antitumor-response-of-gilteritinib-in-lung-cancer-cells-nature-es/ 2026-07-11T06:34:12+00:00 https://keshavmed.com/news/post-marketing-pharmacovigilance-study-of-gilteritinib-and-midostaurin-from-the-faers-database-aml-hub-com-ja/ 2026-07-11T06:34:12+00:00 https://keshavmed.com/news/cholesterol-inhibition-enhances-antitumor-response-of-gilteritinib-in-lung-cancer-cells-nature-ar/ 2026-07-11T06:34:12+00:00 https://keshavmed.com/news/post-marketing-pharmacovigilance-study-of-gilteritinib-and-midostaurin-from-the-faers-database-aml-hub-com-pt/ 2026-07-11T06:34:12+00:00 https://keshavmed.com/news/cholesterol-inhibition-enhances-antitumor-response-of-gilteritinib-in-lung-cancer-cells-nature-ru/ 2026-07-11T06:34:12+00:00 https://keshavmed.com/news/fda-oks-sotorasib-panitumumab-in-kras-g12c-mutant-colorectal-cancer-targeted-oncology-ms/ 2026-07-11T06:34:11+00:00 https://keshavmed.com/news/cholesterol-inhibition-enhances-antitumor-response-of-gilteritinib-in-lung-cancer-cells-nature-th/ 2026-07-11T06:34:11+00:00 https://keshavmed.com/news/dr-mok-on-the-long-term-efficacy-of-first-line-lorlatinib-in-advanced-alk-nsclc-onclive/ 2026-07-11T06:34:11+00:00 https://keshavmed.com/news/cholesterol-inhibition-enhances-antitumor-response-of-gilteritinib-in-lung-cancer-cells-nature-vi/ 2026-07-11T06:34:11+00:00 https://keshavmed.com/news/dr-mok-on-the-long-term-efficacy-of-first-line-lorlatinib-in-advanced-alk-nsclc-onclive-zh-tw/ 2026-07-11T06:34:11+00:00 https://keshavmed.com/news/cholesterol-inhibition-enhances-antitumor-response-of-gilteritinib-in-lung-cancer-cells-nature-ms/ 2026-07-11T06:34:11+00:00 https://keshavmed.com/news/dr-mok-on-the-long-term-efficacy-of-first-line-lorlatinib-in-advanced-alk-nsclc-onclive-fr/ 2026-07-11T06:34:11+00:00 https://keshavmed.com/news/fda-oks-sotorasib-panitumumab-in-kras-g12c-mutant-colorectal-cancer-targeted-oncology/ 2026-07-11T06:34:11+00:00 https://keshavmed.com/news/dr-mok-on-the-long-term-efficacy-of-first-line-lorlatinib-in-advanced-alk-nsclc-onclive-de/ 2026-07-11T06:34:11+00:00 https://keshavmed.com/news/fda-oks-sotorasib-panitumumab-in-kras-g12c-mutant-colorectal-cancer-targeted-oncology-zh-tw/ 2026-07-11T06:34:11+00:00 https://keshavmed.com/news/dr-mok-on-the-long-term-efficacy-of-first-line-lorlatinib-in-advanced-alk-nsclc-onclive-ja/ 2026-07-11T06:34:11+00:00 https://keshavmed.com/news/fda-oks-sotorasib-panitumumab-in-kras-g12c-mutant-colorectal-cancer-targeted-oncology-fr/ 2026-07-11T06:34:11+00:00 https://keshavmed.com/news/dr-mok-on-the-long-term-efficacy-of-first-line-lorlatinib-in-advanced-alk-nsclc-onclive-pt/ 2026-07-11T06:34:11+00:00 https://keshavmed.com/news/fda-oks-sotorasib-panitumumab-in-kras-g12c-mutant-colorectal-cancer-targeted-oncology-de/ 2026-07-11T06:34:11+00:00 https://keshavmed.com/news/fda-oks-sotorasib-panitumumab-in-kras-g12c-mutant-colorectal-cancer-targeted-oncology-ja/ 2026-07-11T06:34:11+00:00 https://keshavmed.com/news/fda-oks-sotorasib-panitumumab-in-kras-g12c-mutant-colorectal-cancer-targeted-oncology-pt/ 2026-07-11T06:34:11+00:00 https://keshavmed.com/news/fda-oks-sotorasib-panitumumab-in-kras-g12c-mutant-colorectal-cancer-targeted-oncology-es/ 2026-07-11T06:34:11+00:00 https://keshavmed.com/news/fda-oks-sotorasib-panitumumab-in-kras-g12c-mutant-colorectal-cancer-targeted-oncology-ar/ 2026-07-11T06:34:11+00:00 https://keshavmed.com/news/fda-oks-sotorasib-panitumumab-in-kras-g12c-mutant-colorectal-cancer-targeted-oncology-ru/ 2026-07-11T06:34:11+00:00 https://keshavmed.com/news/fda-oks-sotorasib-panitumumab-in-kras-g12c-mutant-colorectal-cancer-targeted-oncology-id/ 2026-07-11T06:34:11+00:00 https://keshavmed.com/news/fda-oks-sotorasib-panitumumab-in-kras-g12c-mutant-colorectal-cancer-targeted-oncology-th/ 2026-07-11T06:34:11+00:00 https://keshavmed.com/news/fda-oks-sotorasib-panitumumab-in-kras-g12c-mutant-colorectal-cancer-targeted-oncology-vi/ 2026-07-11T06:34:11+00:00 https://keshavmed.com/news/anktiva-immunotherapy-aids-survival-in-recurrent-glioblastoma-trial-rare-cancer-news-fr/ 2026-07-11T06:34:10+00:00 https://keshavmed.com/news/anktiva-immunotherapy-aids-survival-in-recurrent-glioblastoma-trial-rare-cancer-news-de/ 2026-07-11T06:34:10+00:00 https://keshavmed.com/news/anktiva-immunotherapy-aids-survival-in-recurrent-glioblastoma-trial-rare-cancer-news-ja/ 2026-07-11T06:34:10+00:00 https://keshavmed.com/news/anktiva-immunotherapy-aids-survival-in-recurrent-glioblastoma-trial-rare-cancer-news-pt/ 2026-07-11T06:34:10+00:00 https://keshavmed.com/news/anktiva-immunotherapy-aids-survival-in-recurrent-glioblastoma-trial-rare-cancer-news-es/ 2026-07-11T06:34:10+00:00 https://keshavmed.com/news/anktiva-immunotherapy-aids-survival-in-recurrent-glioblastoma-trial-rare-cancer-news-ar/ 2026-07-11T06:34:10+00:00 https://keshavmed.com/news/anktiva-immunotherapy-aids-survival-in-recurrent-glioblastoma-trial-rare-cancer-news-ru/ 2026-07-11T06:34:10+00:00 https://keshavmed.com/news/dr-mok-on-the-long-term-efficacy-of-first-line-lorlatinib-in-advanced-alk-nsclc-onclive-es/ 2026-07-11T06:34:10+00:00 https://keshavmed.com/news/anktiva-immunotherapy-aids-survival-in-recurrent-glioblastoma-trial-rare-cancer-news-id/ 2026-07-11T06:34:10+00:00 https://keshavmed.com/news/dr-mok-on-the-long-term-efficacy-of-first-line-lorlatinib-in-advanced-alk-nsclc-onclive-ar/ 2026-07-11T06:34:10+00:00 https://keshavmed.com/news/anktiva-immunotherapy-aids-survival-in-recurrent-glioblastoma-trial-rare-cancer-news-th/ 2026-07-11T06:34:10+00:00 https://keshavmed.com/news/dr-mok-on-the-long-term-efficacy-of-first-line-lorlatinib-in-advanced-alk-nsclc-onclive-ru/ 2026-07-11T06:34:10+00:00 https://keshavmed.com/news/anktiva-immunotherapy-aids-survival-in-recurrent-glioblastoma-trial-rare-cancer-news-vi/ 2026-07-11T06:34:10+00:00 https://keshavmed.com/news/dr-mok-on-the-long-term-efficacy-of-first-line-lorlatinib-in-advanced-alk-nsclc-onclive-id/ 2026-07-11T06:34:10+00:00 https://keshavmed.com/news/anktiva-immunotherapy-aids-survival-in-recurrent-glioblastoma-trial-rare-cancer-news-ms/ 2026-07-11T06:34:10+00:00 https://keshavmed.com/news/dr-mok-on-the-long-term-efficacy-of-first-line-lorlatinib-in-advanced-alk-nsclc-onclive-th/ 2026-07-11T06:34:10+00:00 https://keshavmed.com/news/dr-mok-on-the-long-term-efficacy-of-first-line-lorlatinib-in-advanced-alk-nsclc-onclive-vi/ 2026-07-11T06:34:10+00:00 https://keshavmed.com/news/dr-mok-on-the-long-term-efficacy-of-first-line-lorlatinib-in-advanced-alk-nsclc-onclive-ms/ 2026-07-11T06:34:10+00:00 https://keshavmed.com/news/anktiva-immunotherapy-aids-survival-in-recurrent-glioblastoma-trial-rare-cancer-news/ 2026-07-11T06:34:10+00:00 https://keshavmed.com/news/anktiva-immunotherapy-aids-survival-in-recurrent-glioblastoma-trial-rare-cancer-news-zh-tw/ 2026-07-11T06:34:10+00:00 https://keshavmed.com/news/modeling-nrtis-and-pis-class-drug-therapy-on-the-dynamics-of-hiv-infection-with-real-patient-data-analysis-and-optimized-control-strategy-nature-pt/ 2026-07-11T06:34:09+00:00 https://keshavmed.com/news/modeling-nrtis-and-pis-class-drug-therapy-on-the-dynamics-of-hiv-infection-with-real-patient-data-analysis-and-optimized-control-strategy-nature-es/ 2026-07-11T06:34:09+00:00 https://keshavmed.com/news/modeling-nrtis-and-pis-class-drug-therapy-on-the-dynamics-of-hiv-infection-with-real-patient-data-analysis-and-optimized-control-strategy-nature-ar/ 2026-07-11T06:34:09+00:00 https://keshavmed.com/news/modeling-nrtis-and-pis-class-drug-therapy-on-the-dynamics-of-hiv-infection-with-real-patient-data-analysis-and-optimized-control-strategy-nature-ru/ 2026-07-11T06:34:09+00:00 https://keshavmed.com/news/modeling-nrtis-and-pis-class-drug-therapy-on-the-dynamics-of-hiv-infection-with-real-patient-data-analysis-and-optimized-control-strategy-nature-id/ 2026-07-11T06:34:09+00:00 https://keshavmed.com/news/modeling-nrtis-and-pis-class-drug-therapy-on-the-dynamics-of-hiv-infection-with-real-patient-data-analysis-and-optimized-control-strategy-nature-th/ 2026-07-11T06:34:09+00:00 https://keshavmed.com/news/modeling-nrtis-and-pis-class-drug-therapy-on-the-dynamics-of-hiv-infection-with-real-patient-data-analysis-and-optimized-control-strategy-nature-vi/ 2026-07-11T06:34:09+00:00 https://keshavmed.com/news/modeling-nrtis-and-pis-class-drug-therapy-on-the-dynamics-of-hiv-infection-with-real-patient-data-analysis-and-optimized-control-strategy-nature-ms/ 2026-07-11T06:34:09+00:00 https://keshavmed.com/news/who-releases-updated-recommendations-on-hiv-clinical-management-world-health-organization-who/ 2026-07-11T06:34:09+00:00 https://keshavmed.com/news/who-releases-updated-recommendations-on-hiv-clinical-management-world-health-organization-who-zh-tw/ 2026-07-11T06:34:09+00:00 https://keshavmed.com/news/who-releases-updated-recommendations-on-hiv-clinical-management-world-health-organization-who-fr/ 2026-07-11T06:34:09+00:00 https://keshavmed.com/news/modeling-nrtis-and-pis-class-drug-therapy-on-the-dynamics-of-hiv-infection-with-real-patient-data-analysis-and-optimized-control-strategy-nature/ 2026-07-11T06:34:09+00:00 https://keshavmed.com/news/who-releases-updated-recommendations-on-hiv-clinical-management-world-health-organization-who-de/ 2026-07-11T06:34:09+00:00 https://keshavmed.com/news/modeling-nrtis-and-pis-class-drug-therapy-on-the-dynamics-of-hiv-infection-with-real-patient-data-analysis-and-optimized-control-strategy-nature-zh-tw/ 2026-07-11T06:34:09+00:00 https://keshavmed.com/news/who-releases-updated-recommendations-on-hiv-clinical-management-world-health-organization-who-ja/ 2026-07-11T06:34:09+00:00 https://keshavmed.com/news/modeling-nrtis-and-pis-class-drug-therapy-on-the-dynamics-of-hiv-infection-with-real-patient-data-analysis-and-optimized-control-strategy-nature-fr/ 2026-07-11T06:34:09+00:00 https://keshavmed.com/news/who-releases-updated-recommendations-on-hiv-clinical-management-world-health-organization-who-pt/ 2026-07-11T06:34:09+00:00 https://keshavmed.com/news/modeling-nrtis-and-pis-class-drug-therapy-on-the-dynamics-of-hiv-infection-with-real-patient-data-analysis-and-optimized-control-strategy-nature-de/ 2026-07-11T06:34:09+00:00 https://keshavmed.com/news/who-releases-updated-recommendations-on-hiv-clinical-management-world-health-organization-who-es/ 2026-07-11T06:34:09+00:00 https://keshavmed.com/news/modeling-nrtis-and-pis-class-drug-therapy-on-the-dynamics-of-hiv-infection-with-real-patient-data-analysis-and-optimized-control-strategy-nature-ja/ 2026-07-11T06:34:09+00:00 https://keshavmed.com/news/who-releases-updated-recommendations-on-hiv-clinical-management-world-health-organization-who-ar/ 2026-07-11T06:34:09+00:00 https://keshavmed.com/news/who-releases-updated-recommendations-on-hiv-clinical-management-world-health-organization-who-ru/ 2026-07-11T06:34:08+00:00 https://keshavmed.com/news/ai-guided-mapping-aids-afib-ablation-therapy-american-medical-association-ama-vi/ 2026-07-11T06:34:08+00:00 https://keshavmed.com/news/who-releases-updated-recommendations-on-hiv-clinical-management-world-health-organization-who-id/ 2026-07-11T06:34:08+00:00 https://keshavmed.com/news/ai-guided-mapping-aids-afib-ablation-therapy-american-medical-association-ama-ms/ 2026-07-11T06:34:08+00:00 https://keshavmed.com/news/who-releases-updated-recommendations-on-hiv-clinical-management-world-health-organization-who-th/ 2026-07-11T06:34:08+00:00 https://keshavmed.com/news/drugs-and-antibodies-biological-therapy-against-aids-is-getting-closer-il-sole-24-ore/ 2026-07-11T06:34:08+00:00 https://keshavmed.com/news/who-releases-updated-recommendations-on-hiv-clinical-management-world-health-organization-who-vi/ 2026-07-11T06:34:08+00:00 https://keshavmed.com/news/drugs-and-antibodies-biological-therapy-against-aids-is-getting-closer-il-sole-24-ore-zh-tw/ 2026-07-11T06:34:08+00:00 https://keshavmed.com/news/who-releases-updated-recommendations-on-hiv-clinical-management-world-health-organization-who-ms/ 2026-07-11T06:34:08+00:00 https://keshavmed.com/news/drugs-and-antibodies-biological-therapy-against-aids-is-getting-closer-il-sole-24-ore-fr/ 2026-07-11T06:34:08+00:00 https://keshavmed.com/news/ai-guided-mapping-aids-afib-ablation-therapy-american-medical-association-ama/ 2026-07-11T06:34:08+00:00 https://keshavmed.com/news/ai-guided-mapping-aids-afib-ablation-therapy-american-medical-association-ama-zh-tw/ 2026-07-11T06:34:08+00:00 https://keshavmed.com/news/ai-guided-mapping-aids-afib-ablation-therapy-american-medical-association-ama-fr/ 2026-07-11T06:34:08+00:00 https://keshavmed.com/news/ai-guided-mapping-aids-afib-ablation-therapy-american-medical-association-ama-de/ 2026-07-11T06:34:08+00:00 https://keshavmed.com/news/ai-guided-mapping-aids-afib-ablation-therapy-american-medical-association-ama-ja/ 2026-07-11T06:34:08+00:00 https://keshavmed.com/news/ai-guided-mapping-aids-afib-ablation-therapy-american-medical-association-ama-pt/ 2026-07-11T06:34:08+00:00 https://keshavmed.com/news/ai-guided-mapping-aids-afib-ablation-therapy-american-medical-association-ama-es/ 2026-07-11T06:34:08+00:00 https://keshavmed.com/news/ai-guided-mapping-aids-afib-ablation-therapy-american-medical-association-ama-ar/ 2026-07-11T06:34:08+00:00 https://keshavmed.com/news/ai-guided-mapping-aids-afib-ablation-therapy-american-medical-association-ama-ru/ 2026-07-11T06:34:08+00:00 https://keshavmed.com/news/ai-guided-mapping-aids-afib-ablation-therapy-american-medical-association-ama-id/ 2026-07-11T06:34:08+00:00 https://keshavmed.com/news/ai-guided-mapping-aids-afib-ablation-therapy-american-medical-association-ama-th/ 2026-07-11T06:34:08+00:00